Updated · University of California San Diego · Jun 8
Moores Cancer Center Showcases 5 ASCO 2026 Results, Led by 13.2-Month Pancreatic Cancer Survival
Updated
Updated · University of California San Diego · Jun 8
Moores Cancer Center Showcases 5 ASCO 2026 Results, Led by 13.2-Month Pancreatic Cancer Survival
3 articles · Updated · University of California San Diego · Jun 8
Summary
Five Moores Cancer Center highlights at ASCO 2026 were led by the Phase 3 RASolute 302 trial, where daraxonrasib extended median overall survival to 13.2 months from 6.6 months in previously treated metastatic pancreatic cancer.
A separate Phase 2a pancreatic study presented by Peter Vu showed atebimetinib plus modified gemcitabine/nab-paclitaxel reached 17.3 months median overall survival in first-line metastatic disease, outperforming historical benchmarks across patients regardless of mutation status.
In gynecologic cancer, updated Phase 3 NRG-GY018 data in 809 endometrial cancer patients showed pembrolizumab plus carboplatin/paclitaxel maintained an overall survival benefit, including a 9.3-month advantage in the pMMR group after nearly four years of follow-up.
For rare cancers, final DART results covered 727 eligible patients across 53 cohorts and found nearly half showed clinical activity, while more than 10% achieved durable responses lasting two years or longer.
The Chicago meeting also highlighted broader care issues, with H. Irene Su chairing an early-onset cancer session focused on oncofertility access for young patients in resource-constrained settings.
A new drug doubles pancreatic cancer survival. What does this mean for other historically 'undruggable' RAS-driven cancers?
With a new pancreatic cancer drug showing major promise, how will its high cost and side effects impact real-world patient access?
As cancer diagnoses rise in young adults, how can global healthcare ensure equitable access to critical oncofertility programs?
Unprecedented Survival Gains with Daraxonrasib in Metastatic Pancreatic Cancer: Results from the RASolute 302 Phase III Trial
Overview
The 2026 ASCO Annual Meeting revealed groundbreaking results for patients with previously treated metastatic pancreatic cancer. The phase III RASolute 302 trial, presented by leading oncologists, showed that daraxonrasib, a multiselective RAS(ON) inhibitor, nearly doubled median overall survival compared to standard chemotherapy. Patients taking daraxonrasib also experienced a 60% reduction in the risk of death, along with significant improvements in progression-free survival and objective response rate. These findings mark a major advance in pancreatic cancer treatment, offering new hope and setting the stage for daraxonrasib to become a new standard of care.